TUESDAY, june 16 2:00pM ET
Leveraging a de-risked technology platform to advance a
high-value diagnostic and therapeutic pipeline
Jed A. Latkin
Chief Executive Officer, Chief Financial Officer and Chief Operating Officer
Previously was a Portfolio Manager at Nagel Avenue Capital beginning 2010 and at ING Investment Management from 2006-2010, Morgan Stanley Investment banking (2002-2006)
Previously served as CFO of Viper Powersports, CEO of End of Life Petroleum Holdings, CEO of Black Elk Energy, Portfolio Manager of Precious Capital and CFO of West Ventures
Currently serves on the boards of the Renewable Fuels Association and Buffalo Lake Advanced Biofuels
MBA finance - Columbia Grad School of Business
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care.
The Company focuses on the development of innovative immunodiagnostic agents and immunotherapeutics that can and will make a difference for individuals, as well as their families, physicians and care givers, touched by devastating conditions like cancer, autoimmune, infectious and inflammatory diseases. For patients and physicians, we aspire to provide innovative immunodiagnostic agents and therapies to improve patient care for serious diseases. For investors, we aim to deliver superior growth through our focus developing our innovative Manocept™ platform and driving efficient business processes. For our employees, we provide a culture that focuses on the direct contributions our efforts make for the patients we serve and an innovative development environment for new breakthrough products.